ASCO 2020: Post-surgery osimertinib delays disease recurrence in patients with localised non-small cell lung cancer
Treatment with targeted therapy osimertinib following surgery for localised non-small cell lung cancer (NSCLC) with…
Browsing: EGFR tyrosine kinase inhibitor